{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T02:05:22Z","timestamp":1779501922824,"version":"3.53.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. In 2021, Israel's Ministry of Health launched a national program to screen high-risk populations, especially immigrants from former Soviet Union countries, aiming to reduce HCV-related morbidity and mortality. This study evaluates the success of Maccabi Health Services (MHS) in implementing the screening program before and after the intervention, focusing on detection, treatment, and cure rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective interrupted time-series cohort study was conducted among MHS members born in former Soviet Union countries, between 2019 and 2024. The intervention included proactive referrals for HCV antibody testing, educational messaging, and removal of bureaucratic barriers. Key outcomes were number of tests performed, positivity rates, polymerase chain reaction (PCR) confirmation, initiation of direct-acting antiviral treatment, and sustained virologic response (SVR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 179\u2005658 eligible members, 82.3% were screened after the intervention (compared to only 14.2% before). The rate of positive antibody tests dropped from 2.6% preintervention to 1%\u20131.1% postintervention. Ninety-three percent of antibody-positive individuals underwent PCR confirmation, with 52% testing positive. Eighty-four percent of PCR-positive patients started treatment, with higher initiation rates in the early intervention group. Sixty-nine percent of treated patients underwent SVR testing after treatment, with a median time of 106 days from treatment completion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The proactive intervention by MHS led to a significant increase in screening coverage, detection, and treatment among the at-risk population. Removing barriers, providing education, and regular reminders were key to the program's success. This structured approach can serve as a model for screening programs in other populations and countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag278","type":"journal-article","created":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T21:08:00Z","timestamp":1777842480000},"source":"Crossref","is-referenced-by-count":0,"title":["Implementation of a Hepatitis C Screening Program for At-Risk Former Soviet-Bloc Immigrants in a Large Health Maintenance Organization"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9440-5592","authenticated-orcid":false,"given":"Daniella","family":"Rahamim-Cohen","sequence":"first","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bar","family":"Cohen","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-1924","authenticated-orcid":false,"given":"Dor","family":"Atias","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]},{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1206-1516","authenticated-orcid":false,"given":"Afif","family":"Nakhleh","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]},{"name":"Institute of Endocrinology, Diabetes and Metabolism, Rambam Health Care Campus , Haifa ,","place":["Israel"]},{"name":"Azrieli Faculty of Medicine, Bar-Ilan University , Safed ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ori","family":"Liran","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]},{"name":"Family Medicine Department, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izana","family":"Kaplan Lavi","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Azuri","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]},{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]},{"name":"Family Medicine Department, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-6596","authenticated-orcid":false,"given":"Limor","family":"Adler","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]},{"name":"Family Medicine Department, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley Shapiro","family":"Ben David","sequence":"additional","affiliation":[{"name":"Division of Health, Maccabi Healthcare Services , Tel Aviv ,","place":["Israel"]},{"name":"Family Medicine Department, Gray Faculty of Medical and Health Sciences, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"2026052221220982100_ofag278-B1","author":"World Health Organization.","year":"2024"},{"key":"2026052221220982100_ofag278-B2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S2468-1253(24)00442-4","article-title":"Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis","volume":"10","author":"Artenie","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2026052221220982100_ofag278-B3","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/hep.25688","article-title":"Case-control study of hepatitis B and hepatitis C in older adults: do healthcare exposures contribute to burden of new infections?","volume":"57","author":"Perz","year":"2013","journal-title":"Hepatology"},{"key":"2026052221220982100_ofag278-B4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.26639","article-title":"The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection","volume":"59","author":"Grebely","year":"2014","journal-title":"Hepatology"},{"key":"2026052221220982100_ofag278-B5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"2026052221220982100_ofag278-B6","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1053\/j.gastro.2008.09.014","article-title":"Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C\u2013related advanced liver disease","volume":"136","author":"Lok","year":"2009","journal-title":"Gastroenterology"},{"key":"2026052221220982100_ofag278-B7","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin","volume":"139","author":"Swain","year":"2010","journal-title":"Gastroenterology"},{"key":"2026052221220982100_ofag278-B8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamainternmed.2022.5699","article-title":"Association of direct-acting antiviral therapy with liver and nonliver complications and long-term mortality in patients with chronic hepatitis C","volume":"183","author":"Ogawa","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2026052221220982100_ofag278-B9","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"2026052221220982100_ofag278-B10","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1002\/hep.30303","article-title":"Impact of all-oral direct-acting antivirals on clinical and economic outcomes in patients with chronic hepatitis C in the United States","volume":"69","author":"Park","year":"2019","journal-title":"Hepatology"},{"key":"2026052221220982100_ofag278-B11","volume-title":"Eliminating the public health problem of hepatitis B and C in the United States: phase one report","author":"Strom","year":"2016"},{"key":"2026052221220982100_ofag278-B12","volume-title":"The global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections [press release]","author":"World Health Organization.","year":"2022"},{"key":"2026052221220982100_ofag278-B13","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/liv.15446","article-title":"Securing wider EU commitment to the elimination of hepatitis C virus","volume":"43","author":"Wedemeyer","year":"2023","journal-title":"Liver Int"},{"key":"2026052221220982100_ofag278-B14","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13584-017-0172-1","article-title":"Multi-disciplinary patient-centered model for the expedited provision of costly therapies in community settings: the case of new medication for hepatitis C","volume":"6","author":"Avisar","year":"2017","journal-title":"Isr J Health Policy Res"},{"key":"2026052221220982100_ofag278-B15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1007\/s12325-024-03102-6","article-title":"Road to hepatitis C elimination in Israel: improvements in linkage to care (2009-2020)","volume":"42","author":"Basson","year":"2025","journal-title":"Adv Ther"},{"key":"2026052221220982100_ofag278-B16","volume-title":"The national program for hepatitis C eradication in Israel","author":"Israeli Ministry of Health.","year":"2021"},{"key":"2026052221220982100_ofag278-B17","author":"European Association for the Study of the Liver."},{"key":"2026052221220982100_ofag278-B18","volume-title":"Patterns of integration into Israeli society among immigrants from the former Soviet Union over the past three decades: follow up study","author":"Konstantinov","year":"2024"},{"key":"2026052221220982100_ofag278-B19","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1572-0241.2008.01789.x","article-title":"High prevalence of hepatitis C virus infection among immigrants from the former Soviet Union in the New York City metropolitan area: results of a community-based screening program","volume":"103","author":"Batash","year":"2008","journal-title":"Am Coll Gastroenterol"},{"key":"2026052221220982100_ofag278-B20","doi-asserted-by":"crossref","first-page":"ofx109","DOI":"10.1093\/ofid\/ofx109","article-title":"Implementation of a large system-wide hepatitis C virus screening and linkage to care program for Baby Boomers","volume":"4","author":"Castrej\u00f3n","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2026052221220982100_ofag278-B21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3122\/jabfm.2024.240088R1","article-title":"Electronically-delivered push notifications improve patient adherence to preventive care","volume":"38","author":"Lesser","year":"2025","journal-title":"J Am Board Fam Med"},{"key":"2026052221220982100_ofag278-B22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/bjc.2015.36","article-title":"Text-message reminders increase uptake of routine breast screening appointments: a randomised controlled trial in a hard-to-reach population","volume":"112","author":"Kerrison","year":"2015","journal-title":"Br J Cancer"},{"key":"2026052221220982100_ofag278-B23","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2026052221220982100_ofag278-B24","author":"Israel Society of Obstetrics and Gynecology; Israeli Society for Maternal-Fetal Medicine."},{"key":"2026052221220982100_ofag278-B25","doi-asserted-by":"crossref","first-page":"B2","DOI":"10.1016\/j.ajog.2017.07.039","article-title":"Hepatitis C in pregnancy: screening, treatment, and management","volume":"217","author":"Hughes","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2026052221220982100_ofag278-B26","doi-asserted-by":"crossref","first-page":"38.e1","DOI":"10.1016\/j.ajog.2008.03.052","article-title":"Pregnancy complications associated with hepatitis C: data from a 2003-2005 Washington state birth cohort","volume":"199","author":"Pergam","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"2026052221220982100_ofag278-B27","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/jvh.13752","article-title":"Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive","volume":"29","author":"Carey","year":"2022","journal-title":"J Viral Hepat"},{"key":"2026052221220982100_ofag278-B28"},{"key":"2026052221220982100_ofag278-B29","doi-asserted-by":"crossref","first-page":"e0269250","DOI":"10.1371\/journal.pone.0269250","article-title":"Epidemiology of hepatitis B virus and\/or hepatitis C virus infections among people living with human immunodeficiency virus in Africa: a systematic review and meta-analysis","volume":"17","author":"Kenfack-Momo","year":"2022","journal-title":"PLoS One"},{"key":"2026052221220982100_ofag278-B30","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/jmv.21734","article-title":"Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: social factors are important predictors after adjusting for known risk factors","volume":"82","author":"Meffre","year":"2010","journal-title":"J Med Virol"},{"key":"2026052221220982100_ofag278-B31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2147\/CLEP.S43926","article-title":"Socioeconomic status in HCV infected patients\u2014risk and prognosis","volume":"5","author":"Omland","year":"2013","journal-title":"Clin Epidemiol"},{"key":"2026052221220982100_ofag278-B32","doi-asserted-by":"crossref","first-page":"166","DOI":"10.14745\/ccdr.v44i78a03","article-title":"Barriers to and facilitators of hepatitis C virus screening and testing: a scoping review","volume":"44","author":"Shehata","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"2026052221220982100_ofag278-B33","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1186\/s12889-023-16017-8","article-title":"Barriers and enablers to testing for hepatitis C virus infection in people who inject drugs\u2014a scoping review of the qualitative evidence","volume":"23","author":"Balsom","year":"2023","journal-title":"BMC Public Health"},{"key":"2026052221220982100_ofag278-B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2458-11-293","article-title":"Reasons for compliance or noncompliance with advice to test for hepatitis C via an internet-mediated blood screening service: a qualitative study","volume":"11","author":"Zuure","year":"2011","journal-title":"BMC Public Health"},{"key":"2026052221220982100_ofag278-B35","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s10900-014-9932-9","article-title":"Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic","volume":"39","author":"Morano","year":"2014","journal-title":"J Community Health"},{"key":"2026052221220982100_ofag278-B36","doi-asserted-by":"crossref","first-page":"S334","DOI":"10.1093\/infdis\/jiad198","article-title":"Lessons learned from global hepatitis C elimination programs","volume":"229","author":"Handanagic","year":"2024","journal-title":"J Infect Dis"},{"key":"2026052221220982100_ofag278-B37","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/postgradmedj-2017-135273","article-title":"Information provided by diagnostic and screening tests: improving probabilities","volume":"94","author":"Weatherall","year":"2018","journal-title":"Postgrad Med J"},{"key":"2026052221220982100_ofag278-B38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.5604\/01.3001.0011.7385","article-title":"Direct acting antivirals improve HCV treatment initiation and adherence among underserved African Americans","volume":"17","author":"Beck","year":"2018","journal-title":"Ann Hepatol"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag278\/68224676\/ofag278.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag278\/68224676\/ofag278.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/5\/ofag278\/68224676\/ofag278.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T01:22:16Z","timestamp":1779499336000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag278\/8670203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag278","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,28]]},"article-number":"ofag278"}}